Avista Capital Partners has made a $48.5 million growth investment in OptiNose to help the company bring to market its new nasal drug delivery device. The company has previously raised venture financing from a group of VC investors, including Entrepreneurs Fund, inSpire Ventures and WFD Ventures.
© 2020 PitchBook Data. All rights reserved. PitchBook is a financial technology company that provides data on the capital markets.